aminopeptidas
enzym
select
hydrolyz
amino
acid
residu
nterminu
protein
peptid
import
proper
function
prokaryot
eukaryot
cell
often
central
player
devast
human
diseas
like
cancer
malaria
diabet
largest
aminopeptidas
group
includ
enzym
contain
metal
ion
activ
center
often
determin
type
inhibitor
suitabl
effect
ligand
mostli
bind
noncoval
mode
form
complex
metal
ion
present
sever
approach
design
inhibitor
metalloaminopeptidas
optim
structur
consid
potenti
lead
drug
discoveri
process
endogen
infecti
diseas
crown
aminotermin
modif
nascent
polypeptid
common
process
event
occur
nearli
protein
aminopeptidas
class
enzym
play
pivot
role
process
aminopeptidas
ec
e
hydrolasespeptidasesaminopeptidas
accord
classif
intern
union
biochemistri
molecular
biolog
proteolyt
enzym
hydrolyz
peptid
bond
amino
termini
polypeptid
chain
may
hydrolyz
first
peptid
bond
polypeptid
chain
releas
singl
amino
acid
residu
aminopeptidas
strict
sens
may
remov
dipeptid
tripeptid
dipeptidyland
tripeptidylpeptidas
polypeptid
substrat
regard
catalyt
mechan
aminopeptidas
metalloenzym
cystein
serin
peptidas
also
includ
group
review
focus
strict
metalloaminopeptidas
constitut
largest
homogen
class
enzym
use
one
two
metal
ion
activ
site
specif
releas
ntermin
amino
acid
residu
polypeptid
protein
sinc
paper
deal
aminopeptidas
publish
medlin
databas
aminopeptidas
ubiquit
enzym
wide
distribut
throughout
biolog
kingdom
found
mani
subcellular
organel
cytoplasm
membran
compon
perform
essenti
cellular
function
aminopeptidas
act
concert
peptidas
complet
divers
proteolyt
pathway
play
vital
role
rang
biolog
process
diseas
situat
process
distinct
angiogenesi
antigen
present
neuropeptid
hormon
process
pregnanc
reproduct
protein
turnov
memori
inflamm
tumor
growth
cancer
metastasi
blood
pressur
hypertens
involv
one
critic
aminopeptidas
enzym
effici
retriev
amino
acid
dietari
protein
endogen
protein
degrad
protein
turnov
therebi
also
cover
nutrit
role
addit
book
hooper
lendeckel
describ
role
aminopeptidas
biolog
medicin
sever
excel
review
variou
aspect
biolog
applic
inhibitor
publish
therefor
limit
review
select
recent
achiev
field
although
present
certain
histor
context
classif
aminopeptidas
often
base
mechan
catalysi
structur
activ
site
substrat
specif
broad
narrow
molecular
properti
nomenclatur
mani
peptidas
determin
prefer
requir
particular
ntermin
amino
acid
rapidli
accumul
data
cover
new
repres
proteolyt
enzym
requir
develop
integr
sourc
inform
role
fulfil
merop
databas
http
meropssangeracuk
use
hierarch
structurebas
classif
enzym
databas
reli
fact
enzym
perform
similar
chemic
function
differ
organ
gener
turn
similar
overal
threedimension
structur
also
show
signific
conserv
amino
acid
sequenc
polypeptid
chain
length
domain
organ
particular
region
activ
site
high
degre
conserv
residu
ident
structur
posit
observ
merop
peptidas
inform
databas
proteas
assign
certain
famili
basi
statist
signific
similar
amino
acid
sequenc
famili
thought
homolog
group
togeth
clan
clan
consist
famili
peptidas
believ
share
singl
evolutionari
origin
evidenc
similar
tertiari
structur
andor
activ
site
architectur
fifteen
clan
metalloproteas
identifi
metalloaminopeptidas
found
six
design
largest
one
contain
famili
mf
mg
mh
mn
mq
famili
clan
unit
presenc
hexxh
motif
two
residu
zinc
ligand
glu
catalyt
function
clan
mf
two
zinc
ion
activ
site
mg
pitabread
fold
contain
two
cobalt
two
manganes
ion
activ
center
mq
typic
two
zinc
ion
consist
one
famili
peptidas
respect
mh
clan
form
heterogen
group
contain
varieti
zincdepend
exopeptidas
structur
show
similar
protein
fold
cocatalyt
zinc
peptidas
contain
two
atom
zinc
per
molecul
five
amino
acid
ligand
clanmn
contain
one
enzym
e
damino
acidspecif
aminopeptidas
bacillu
subtili
although
metalloaminopeptidas
occur
type
organ
mammalian
enzym
amongst
first
proteas
discov
tissu
therefor
intens
studi
human
enzym
particularli
increas
interest
sinc
alter
function
regul
underlin
mani
human
diseas
exampl
leucin
aminopeptidas
lap
ec
belong
famili
extens
studi
play
key
role
metabol
protein
biolog
activ
peptid
enzym
perhap
first
isol
cytosol
exopeptidas
broad
substrat
specif
ubiquit
natur
present
anim
also
plant
bacteria
medic
biolog
import
function
metabol
hormon
neurotransmiss
cell
matur
turnov
protein
includ
util
exogen
protein
nutrient
substanc
elimin
nonfunct
protein
human
lap
import
process
antigen
peptid
determin
immunodomin
variou
peptid
well
develop
human
eye
len
cataract
proteas
play
vital
role
progress
cancer
may
also
import
function
earli
event
hiv
infect
thu
serum
activ
enzym
may
use
surrog
marker
hiv
infect
respons
chemotherapi
anoth
exampl
medic
import
enzym
microsom
aminopeptidas
belong
famili
known
also
aminopeptidas
n
alanyl
aminopeptidas
ec
biolog
system
primari
peptid
substrat
includ
wide
varieti
neuropeptid
hormon
establish
myelomonocyt
marker
leukemia
type
receptor
human
coronaviru
cytomegaloviru
mediat
inflamm
cell
invas
regul
blood
pressur
pathogenesi
hypertens
regul
analgesia
via
metabol
endorphin
enkephalin
furthermor
also
regul
bioavail
endometrium
therefor
may
contribut
process
angiogenesi
also
play
key
role
physiolog
patholog
process
embryogenesi
immun
respons
angiogenesi
tumor
cell
invas
metastasi
methionin
aminopeptidas
aminopeptidas
metap
ec
belong
famili
exampl
peptidas
exhibit
narrow
specif
gener
respons
remov
methionin
aminoterminu
newli
synthes
protein
maintain
stringent
specif
ntermin
methionin
accept
natur
amino
acid
residu
also
strong
prefer
small
uncharg
second
residu
peptid
chain
sinc
mammalian
enzym
play
critic
role
regul
posttransl
process
protein
synthesi
play
import
role
develop
malign
differ
type
cancer
human
aminopeptidas
also
involv
neurofibromatosi
one
common
tumor
predisposit
syndrom
although
scarc
also
report
aminopeptidas
isol
character
vertebr
speci
exemplifi
recent
find
fish
carp
red
sea
bream
bird
chicken
far
inform
known
insect
aminopeptidas
n
one
membran
protein
identifi
receptor
cri
protein
variou
speci
cri
protein
produc
bacillu
thuringiensi
toxic
insect
thu
strain
exploit
commerci
bioinsecticid
aminopeptidas
involv
degrad
insect
neuropeptid
also
studi
respect
group
metalloaminopeptidas
explor
intens
bacteri
origin
first
studi
enzym
carri
year
ago
sinc
larg
number
aminopeptidas
microbi
origin
character
may
local
cytoplasm
membran
associ
cell
envelop
secret
extracellular
media
interest
enzym
stem
potenti
act
target
combat
bacteri
diseas
respect
wide
varieti
structur
divers
aminopeptidas
recent
isol
character
rang
bacteri
speci
includ
aminopeptidas
p
isol
common
strain
escherichia
coli
aminopeptidas
pathogen
mycobacterium
tuberculosi
leucin
aminopeptidas
helicobact
pylori
coldact
aminopeptidas
psychrotrop
colwellia
psychrerythraea
thermophil
enzym
geobacillu
thermoleovoran
extracellular
zinc
metalloproteas
put
virul
factor
involv
pathogen
fish
pathogen
vibrio
anguillarum
lysinespecif
enzym
unusu
resist
hyperthermophil
archaeon
pyrococcu
furiosu
clearli
indic
bacteri
aminopeptidas
wide
distribut
vital
import
recent
year
consider
interest
aminopeptidas
parasit
protozoan
caus
import
diseas
human
anim
bird
alanin
leucin
aminopeptidas
plasmodium
falciparum
caus
agent
malaria
signific
parasit
diseas
human
comprehens
studi
aminopeptidas
promis
target
design
antimalari
drug
recent
review
see
anoth
import
enzym
plasmodium
e
aspartyl
aminopeptidas
consid
addit
target
drug
design
intens
studi
role
biochemistri
aminopeptidas
isol
parasit
organ
includ
legionella
pneumophila
caus
agent
legionnair
diseas
eimeria
tenella
caus
hemorrhag
cecal
coccidiosi
young
poultri
babesia
gibsoni
parasit
found
red
blood
cell
transmit
tick
microsporidia
caus
diseas
immunosuppress
patient
ongo
diseas
caus
also
trematod
commonli
known
bloodfluk
affect
hundr
million
peopl
impoverish
area
africa
central
south
america
east
asia
caus
schistosoma
spp
consid
world
health
organ
second
import
malaria
leucin
aminopeptidas
thought
play
central
role
hatch
miracidium
schistosom
egg
therefor
intens
studi
candid
drug
design
similar
motiv
driven
studi
leucin
aminopeptidas
paragonimu
westermani
tissueinvad
trematod
caus
inflammatori
lung
diseas
well
system
infect
includ
cerebr
invas
carnivor
mammal
specif
parasit
aminopeptidas
might
also
consid
target
vaccin
design
shown
fasciola
hepatica
vector
import
freshwat
snailborn
helminthiasi
produc
chronic
liver
infect
cattl
sheep
understand
mechan
action
famili
metalloaminopeptidas
key
import
ration
design
potent
specif
inhibitor
enzym
consequ
obtain
drug
improv
properti
therefor
substanti
effort
made
studi
mode
bind
substrat
transit
state
inhibitor
enzymat
bind
site
well
elucid
threedimension
structur
activ
site
detail
mechan
catalyz
reaction
featur
common
metalloaminopeptidas
activ
site
metal
ion
case
zinc
surround
shell
hydrophil
group
embed
within
larger
environ
hydrophob
group
addit
amino
acid
side
chain
serv
ligand
usual
form
hydrogen
bond
contact
neighbor
residu
perhap
preorder
metal
ion
bind
site
decreas
entrop
cost
bind
structur
activ
site
suggest
number
reaction
path
possibl
two
catalyt
role
metal
ion
might
consid
first
might
stabil
highli
reactiv
hydroxid
ion
therebi
ensur
activ
nucleophil
avail
catalysi
physiolog
ph
mechan
fig
second
posit
charg
metal
ion
may
serv
electrophil
catalyst
complex
oxygen
atom
scissil
peptid
bond
facilit
nucleophil
attack
water
molecul
mechan
b
fig
also
possibl
activ
site
glutam
especi
case
famili
peptidas
act
nucleophil
result
format
coval
enzymeeinhibitor
complex
follow
fast
hydrolysi
water
mechan
c
fig
glutam
assist
process
consid
less
probabl
mechan
b
case
enzym
contain
binuclear
metal
center
substrat
carbonyl
oxygen
coordin
one
hydroxid
ion
bridg
two
metal
ion
act
nucleophil
agent
mechan
fig
may
explain
fact
sever
dinuclear
metallopeptidas
retain
catalyt
activ
convert
mononuclear
catalyt
role
consid
metal
zinc
ion
mechan
metalloaminopeptidas
action
stabil
highli
reactiv
hydroxid
ion
mechan
complex
oxygen
atom
scissil
peptid
bond
facilit
nucleophil
attack
water
molecul
mechan
b
fig
altern
catalyt
mechan
consid
metalloaminopeptidas
glutam
act
nucleophil
e
format
coval
enzymeeinhibitor
complex
fast
hydrolysi
mechan
c
bridg
hydroxid
ion
binuclear
metal
center
mechan
one
typic
exhibit
faster
rate
dinuclear
activ
site
final
case
addit
role
metal
ion
stabil
develop
neg
charg
transit
state
catalyt
mechan
singl
method
elucid
mechan
certain
enzymat
reaction
thu
combin
sever
method
requir
enzym
kinet
prove
mode
catalysi
use
enzym
howev
kinet
data
suggest
possibl
examin
techniqu
evalu
role
metal
ion
usual
studi
metal
exchang
techniqu
particular
role
metal
ion
dinuclear
site
aminopeptidas
famili
toward
peptid
hydrolysi
studi
kinet
spectroscop
method
replac
one
activ
site
zinc
ion
mn
ii
co
ii
ni
ii
zn
ii
cd
ii
import
data
detail
mechan
action
aminopeptidas
also
gain
product
alter
enzym
mean
sitedirect
mutagenesi
good
exampl
studi
role
activ
site
glutam
acid
variou
aminopeptidas
famili
achiev
replac
glutam
acid
either
structur
relat
aspart
acid
possess
acid
side
group
glutamin
lack
acid
side
group
structur
differ
alanin
studi
kinet
properti
mutat
enzym
method
provid
import
insight
domain
organ
architectur
activ
site
aminopeptidas
thu
mechan
action
crystallographi
respect
crystal
structur
nativ
enzym
complex
small
ligand
extrem
use
repres
recent
exampl
see
especi
determin
enzym
bound
inhibitor
consid
transit
state
analogu
also
emerg
power
applic
computeraid
method
mean
studi
mechan
enzymat
reaction
calcul
enabl
research
choos
one
sever
possibl
reaction
pathway
thu
determin
reaction
mechan
establish
structur
transit
state
method
base
knowledg
enzym
threedimension
structur
avail
either
crystallograph
method
obtain
comput
use
homolog
approach
techniqu
repres
exampl
consid
metalloaminopeptidas
see
besid
elucid
function
role
activesit
residu
estim
environ
effect
also
possibl
case
metalloaminopeptidas
popular
techniqu
studi
employ
modifi
substrat
studi
isotop
effect
construct
chemic
model
enzym
activ
site
quit
scarc
due
associ
sever
medic
disord
metalloaminopeptidas
consid
import
target
design
inhibitor
could
potenti
enter
clinic
trial
candid
drug
presenc
metal
ion
activ
center
determin
gener
strategi
appli
develop
synthet
ligand
possess
two
fundament
structur
featur
specif
warhead
portion
dedic
recogn
activ
site
enzym
specif
function
group
creat
appropri
complex
metal
ion
metal
ligand
fragment
incorpor
backbon
contain
optim
side
chain
abl
interact
enzym
bind
pocket
result
noncoval
inhibitor
amino
acid
peptid
structur
natur
substrat
transit
state
product
analogu
appear
suitabl
purpos
inde
major
compound
design
date
characterist
bident
tetrahedr
phosphon
aldehyd
hydrat
gemdiol
form
bident
planar
carboxyl
hydroxam
well
monodent
thiol
classic
exampl
recent
varieti
promis
heteroaromat
miscellan
heteroaromat
base
sulfonamidescarboxylatesamid
inhibitor
metalloaminopeptidas
identifi
random
screen
compound
librari
structur
usual
involv
bident
n
n
n
donor
system
incorpor
rigid
hydrophob
environ
thu
compound
also
act
noncoval
mode
final
natur
product
also
sourc
appropri
effector
group
peptidas
bestatin
prototyp
repres
peptidelik
framework
offer
choic
heteroatom
group
get
involv
activ
site
metal
ion
complex
natur
noncoval
heteroatomrich
system
base
terpen
polyphenol
scaffold
fumagillin
ovalicin
quit
uniqu
exampl
specif
inhibitor
possess
electrophil
moieti
epoxid
capabl
react
nucleophil
side
chain
activ
site
proven
medicin
import
aminopeptidas
n
apn
leucin
aminopeptidas
lap
methionin
aminopeptidas
metap
result
focu
design
inhibitor
primarili
three
enzym
extens
themat
review
recent
publish
present
select
sever
recent
histor
approach
design
optim
inhibitor
metalloaminopeptidas
could
serv
lead
compound
futur
studi
group
proteas
among
de
novo
construct
target
molecul
organophosphoru
compound
name
aaminoalkanephosphon
gener
formula
fig
phosphoru
contain
pseudodipeptid
predominantli
phosphin
probabl
contribut
inhibit
studi
neutral
aminopeptidas
apn
alanyl
lap
leucin
although
phosphonatephosphin
group
rather
weak
zinc
complex
moieti
offer
advantag
structur
electron
featur
similar
amino
acid
peptid
mimet
use
proteas
inhibitor
effect
incorpor
coval
noncoval
bind
group
involv
coordin
catalyt
metal
ion
enzym
activ
site
substrat
structur
phosphoru
modifi
compound
also
uniqu
combin
tetrahedr
shape
consid
mimic
high
energi
transit
state
peptid
bond
hydrolysi
addit
side
chain
aminophosphon
acid
analogu
effect
residu
pseudopeptid
phosphoryl
moieti
give
possibl
structur
optim
substitu
interact
bind
pocket
enzym
fig
fig
appear
effici
inhibitor
lap
k
mm
r
l
enantiom
antipod
strongli
discrimin
order
magnitud
given
exampl
noncod
arylalkyl
deriv
exemplifi
phosphon
homophenylalanin
homotyrosin
bound
preferenti
even
slightli
greater
extent
k
mm
respect
racem
mixtur
fig
promis
affin
k
mm
also
found
extend
linear
homologu
name
acid
result
indic
bind
pocket
leucin
aminopeptidas
accommod
hydrophob
ligand
even
bulkier
indic
substrat
prefer
hydrolas
cleav
substrat
broad
band
specif
howev
hydrophob
charact
ntermini
like
leucin
methionin
isoleucin
valin
etc
process
notic
faster
somewhat
similar
situat
observ
alanyl
aminopeptidas
apn
mammalian
one
orthologu
lower
organ
protozoan
p
falciparum
exampl
phosphon
amino
acid
analogu
strong
hydrophob
charact
phenylalkyl
cycloalkyl
alkyl
compound
fig
inhibit
porcin
kidney
enzym
k
valu
low
micromolar
rang
interest
attempt
map
apn
bind
pocket
rationalis
data
context
substrateinhibitor
structur
relationship
recent
undertaken
specif
apn
determin
use
extens
collect
fluorogen
substrat
bear
natur
nonnatur
residu
obtain
kinet
paramet
correl
activ
correspond
aaminophosphon
inhibitor
surprisingli
turnov
veloc
express
k
cat
k
strength
substrat
bind
describ
k
valu
predict
reliabl
structur
featur
respons
inhibitori
potenc
thu
appropri
residu
incorpor
aaminophosphon
core
prove
indispens
tight
bind
ligand
apn
resembl
substrat
specif
two
aminopeptidas
lap
apn
frequent
studi
togeth
refer
select
newli
develop
ligand
gener
aaminoalkanephosphin
acid
much
potent
inhibitor
leucin
aminopeptidas
exampl
hydrophob
aliphat
compound
fig
express
affin
two
order
magnitud
higher
lap
compar
apn
indic
appropri
k
valu
reason
observ
seem
presenc
two
zinc
ion
bind
site
cytosol
aminopeptidas
lap
contain
two
zinc
ion
apn
contain
one
involv
necepo
portion
interact
metal
ion
definit
result
tighter
bind
contrarili
leucin
aminopeptidas
readili
accept
substitu
contain
nitrogen
atom
thu
achiev
high
differenti
factor
favor
apn
bulki
hydrophob
residu
appropri
modifi
heteroatom
compound
fig
bear
addit
amino
moieti
obtain
aziridinephosphon
ring
open
amin
low
micromolar
inhibitor
apn
effect
lap
worth
note
among
phosphoru
analogu
amino
acid
studi
far
n
acid
appear
activ
toward
apn
avail
broad
collect
appli
aaminophosphon
allow
systemat
structureeact
relationship
context
bind
pocket
prefer
specif
lap
apn
howev
achiev
signific
inhibit
compound
need
extend
interact
pocket
well
three
kind
phosphon
elongationmodif
envisag
provid
dipeptid
transit
state
mimet
formal
structur
result
replac
scissil
amid
bond
phosphonodepsi
phosphonamid
phosphin
moieti
potenti
three
variat
aminopeptidas
inhibit
evalu
detail
leuleu
mimet
lap
target
synthesi
phosphon
analogu
compound
x
fig
describ
earli
work
bartlett
howev
compound
show
moder
potenc
toward
enzym
studi
despit
systemat
computeraid
approach
undertaken
grembecka
et
al
design
new
gener
activ
inhibitor
methodolog
preliminari
valid
ration
structureeact
relationship
obtain
variou
phosphoru
contain
amino
acid
analogu
appli
pseudodipeptid
posit
confirm
idea
addit
portion
albeit
via
pen
pec
bond
pseudodepsidipeptid
bond
peo
found
unfavour
entrop
effect
upon
inhibitor
bind
oxygeneoxygen
electrostat
repuls
carbonyl
two
type
analogu
x
nh
x
ch
fig
synthes
evalu
disappointedli
fulli
deprotect
phosphonamid
appear
unstabl
ph
hydrolysi
pen
bond
occur
effect
two
compon
amino
acid
clearli
correl
presenc
free
neighbor
amino
group
side
crucial
effect
bind
thu
despit
promis
compound
accord
comput
predict
compound
theoret
calcul
bind
affin
k
nm
phosphonamid
exclud
practic
reason
turn
phosphin
pseudodipeptid
exhibit
perfect
hydrolyt
stabil
inhibit
constant
nanomolar
rang
rank
among
effect
ligand
lap
report
date
mixtur
two
diastereoisom
leuleu
analogu
show
k
nm
similarli
phosphin
hpheph
hphetyr
mimet
contain
arylalkyl
residu
compound
respect
fig
test
mixtur
four
diastereoisom
chiral
chromatographi
perform
compound
allow
separ
assign
activ
individu
stereoisom
final
k
valu
r
counterpart
l
l
natur
peptid
configur
determin
nm
interestingli
compound
particularli
latter
one
appear
also
effect
inhibitor
apn
k
nm
nm
respect
mixtur
four
diastereoisom
clear
prefer
tyr
residu
posit
indic
signific
termin
phenol
oh
group
observ
explain
format
specif
hydrogen
bond
carboxyl
glu
apn
use
model
homolog
leukotrien
hydrolas
structur
explor
structur
termini
context
lap
versu
apn
select
undertaken
via
parallel
nalkyl
strategi
appropri
amino
acid
build
block
unfortun
final
product
appear
moder
poorli
select
inhibitor
k
enzym
vari
mm
rang
importantli
phosphin
pseudodipeptid
found
excel
inhibitor
parasit
counterpart
lap
apn
use
tool
valid
potenti
target
novel
treatment
malaria
p
falciparum
aminopeptidas
respons
cleavag
neutral
residu
termin
stage
host
haemoglobin
degrad
thu
limit
stage
gener
amino
acid
essenti
parasit
growth
develop
repres
attract
target
develop
novel
antimalari
drug
compound
inhibit
recombin
enzym
potenc
superior
observ
mammalian
peptidas
k
nm
respect
affin
measur
also
elev
k
nm
compar
porcin
apn
k
nm
addit
phosphin
effici
control
growth
p
falciparum
cultur
includ
malaria
cell
line
resist
wellknown
antimalari
chloroquin
final
vivo
studi
use
nonleth
plasmodium
chabaudi
murin
malaria
model
demonstr
treatment
mice
compound
reduc
infect
compar
control
recent
compound
cocrystal
give
insight
activ
site
architectur
mechan
action
aminopeptidas
greatli
facilit
design
new
optim
ligand
potenti
antiparasit
agent
appropri
phosphin
pseudodipeptid
build
block
elong
mean
solut
solidphas
peptid
synthesi
produc
tripeptid
analogu
possess
addit
substitu
optim
compound
report
potent
organophosphoru
inhibitor
alanyl
apn
glutamyl
aminopeptidas
apa
ec
metalloaminopeptidas
report
date
chen
et
al
describ
seri
nanomolar
ligand
mammalian
apn
exemplifi
alapheph
analogu
fig
antinocicept
activ
thank
dual
action
apn
neprilysin
caus
analges
respons
administr
mice
compound
inhibit
equipot
mammalian
alanyl
aminopeptidas
well
bacteri
orthologu
also
serv
ligand
resolv
threedimension
structur
latter
enzym
relat
phosphin
tripeptid
analogu
use
cocrystal
leukotrien
hydrolaseaminopeptidas
prototyp
famili
member
result
substrat
transit
state
bind
detail
togeth
presum
catalyt
mechan
scarc
data
enzym
report
phosphin
pseudotripeptid
gluleuala
analogu
fig
test
mixtur
four
diastereoisom
show
high
affin
toward
zinc
glutamyl
aminopeptidas
mice
recombin
express
k
equal
nm
within
seri
compound
ntermin
pseudoglutamyl
residu
found
crucial
high
potenc
select
exampl
differenti
factor
apa
apn
k
mm
exceed
four
order
magnitud
favor
apa
modif
phosphin
metal
bind
group
order
increas
number
coordin
ion
present
activ
site
repres
anoth
approach
improv
potenc
aminopeptidas
inhibitor
effect
achiev
introduct
neighbor
group
contain
heteroatom
addit
involv
metal
complex
four
type
modif
propos
evalu
recent
alanyl
aminopeptidas
apn
involv
applic
aaminoalkanea
hydroxyalkanephosphin
acid
gener
formula
fig
bisaaminoalkanephosphin
acid
carbamoyl
thiocarbamoyl
aaminoalkanephosphin
acid
structur
variant
previous
describ
bartlett
lap
inhibit
achiev
leuleu
analogu
r
interest
result
report
apn
combin
hydrophob
residu
r
ipr
ibu
nbu
ph
ch
ph
r
ph
ch
ph
ch
pomec
h
allow
regul
enzym
activ
ic
valu
mm
result
correspond
k
nm
interestingli
four
structur
variat
produc
compar
low
micromolar
submicromolar
ic
valu
inhibit
origin
isol
streptomyc
olivoreticuli
year
ago
umezawa
cowork
bestatin
e
ubenimex
fig
one
first
potent
inhibitor
metalloaminopeptidas
broad
spectrum
action
bestatin
extens
investig
biolog
system
vitro
vivo
result
discoveri
sever
interest
properti
compound
abil
induc
apoptosi
cancer
cell
antiangiogen
antimalari
immunomodulatori
effect
present
bestatin
market
japan
appli
treatment
cancer
bacteri
infect
exampl
success
inhibit
aminopeptidas
bestatin
includ
aminopeptidas
n
leucin
aminopeptidas
lap
aminopeptidas
b
ec
lta
hydrolas
bestatin
act
slow
lap
fast
apn
bind
competit
inhibitor
aminopeptidas
resembl
pheleu
dipeptid
substrat
howev
phe
residu
baminoahydroxi
amino
acid
ahydroxi
group
togeth
neighbor
carbonyl
group
coordin
zinc
ion
result
competit
activ
sitedirect
inhibit
bestatin
weaker
inhibitor
aminopeptidas
contain
one
metal
ion
activ
center
apn
apb
much
stronger
enzym
two
metal
ion
lap
featur
explain
larger
amount
interact
made
inhibitor
enzym
metal
ion
activ
center
along
addit
contact
made
side
chain
inhibitor
pocket
enzym
date
sever
stereoselect
synthet
method
lead
desir
bestatin
diastereom
describ
see
recent
review
present
avail
synthet
method
bestatin
modif
absolut
configur
key
issu
respons
good
inhibitori
effect
discrimin
appropri
bind
partner
substrat
inhibitor
proteas
diastereom
bestatin
invers
configur
carbon
atom
hydroxi
group
known
epibestatin
frequent
use
neg
control
biolog
experi
structur
bestatin
also
subject
sever
modif
hope
improv
inhibitori
pharmacolog
properti
exampl
deriv
bestatin
thioamid
compound
fig
parahydroxybestatin
scaffold
bestatin
also
use
design
activ
compound
triand
tetrapeptid
better
inhibitor
aminopeptidas
n
compar
bestatin
due
increas
amount
contact
made
pocket
enzym
side
chain
inhibitor
case
hydrophob
charact
phe
leu
val
hydroxam
acid
nhydroxyamid
consid
analogu
carboxyl
acid
amid
uniqu
combin
featur
group
simultan
hydroxam
moieti
effect
planar
bident
metal
chelat
system
close
structur
similar
productssubstr
peptid
bond
hydrolysi
metalcomplex
properti
make
attract
warhead
construct
inhibitor
target
toward
metallodepend
proteas
synthesi
problemat
usual
involv
onestep
transform
acid
ester
use
appropri
hydroxylamin
deriv
accordingli
onesid
optim
hydroxam
analogu
acid
amino
acid
peptid
found
biomed
relev
promis
applic
associ
inhibit
matrix
metalloproteinas
perspect
target
anticanc
therapi
matrix
metalloproteinas
involv
normal
abnorm
tissu
remodel
angiogenesi
tumor
metastasi
potent
regul
hydroxam
eg
batimastat
marimastat
reach
advanc
phase
clinic
trial
final
fail
side
effect
associ
cross
interact
metal
contain
protein
fundament
work
metalloaminopeptidas
inhibit
aaminohydroxam
perform
chan
et
al
concern
leucin
aminopeptidas
deriv
hydrophob
amino
acid
exemplifi
lleunhoh
compound
fig
regul
enzym
activ
k
valu
micromolar
rang
ctermin
modifi
compound
lleu
amid
alcohol
hydrazid
togeth
amino
acid
alon
much
less
potent
typic
least
ratio
observ
consist
subsequ
studi
seri
phenylalanin
deriv
target
toward
apn
compound
fig
appear
moder
inhibitor
enzym
lleunhoh
lphenhoh
overpow
correspond
thiol
indic
much
tighter
individu
sulfurezinc
interact
bident
oxygenezinc
bind
sinc
choic
hydroxam
acid
inhibitor
necessarili
base
amino
acid
skeleton
differ
metalloaminopeptidas
report
literatur
repres
select
recent
exampl
present
fig
compound
bear
hydrophob
substitu
identifi
screen
natur
synthet
compound
librari
appear
equipot
bestatin
apn
compound
control
basic
fibroblast
growthfactorinduc
invas
endotheli
cell
low
micromolar
rang
hydroxam
highli
select
exert
action
toward
member
matrix
metalloproteas
famili
interest
hydroxam
base
inhibitor
also
develop
methionin
aminopeptidas
differ
organ
hu
et
al
describ
synthesi
compound
possess
addit
substitut
hydroxam
nitrogen
atom
nhydroxydipeptid
deriv
metgli
compound
fig
allow
structur
optim
side
molecul
product
inhibit
bacteri
well
form
human
metap
slight
prefer
e
coli
enzym
cooper
action
ntermin
amino
group
two
hydroxam
oxygen
atom
toward
two
catalyt
metal
ion
activ
center
suggest
bind
pattern
bacteri
form
serv
also
model
comparison
activ
acid
variant
ctermini
heteroaromat
hydroxam
acid
exemplifi
fig
found
superior
inhibitor
correspond
acid
ester
amid
hydrazid
alcohol
nitril
toward
distinct
metalloform
certain
metalloaminopeptidas
promis
target
anticanc
therapi
human
also
exploit
develop
antibacteri
antifung
antiparasit
agent
zinc
p
falciparum
aminopeptidas
activ
explor
context
describ
section
devot
organophosphoru
compound
dual
function
amidehydroxam
templat
also
use
target
malaria
enzym
compound
develop
consist
three
portion
hydroxam
acid
termini
dedic
zn
ii
complex
hydrophob
asubstitu
amid
function
serv
extens
structur
diversif
use
bulki
hydrophob
amin
amid
format
exemplifi
fig
yield
potent
inhibitor
parasit
enzym
ic
valu
low
nanomolar
rang
importantli
consecut
iter
optim
gave
deriv
character
spectacular
select
versu
mammalian
orthologu
compound
activ
parasit
growth
inhibit
display
good
pharmacokinet
properti
tosedostat
fig
seem
attract
novel
pharmacolog
activ
product
among
hydroxam
acid
metallopeptidas
inhibitor
oral
avail
cyclopentyl
ester
prodrug
convert
vivo
intracellularli
activ
acid
metabolit
latter
potent
inhibitor
number
aminopeptidas
includ
leucin
aminopeptidas
aminopeptidas
n
puromycin
sensit
aminopeptidas
leukotrien
hydrolaseaminopeptidas
ic
nanomolar
rang
exert
antiprolif
effect
tumor
cell
line
vitro
vivo
exhibit
time
potenc
bestatin
propos
mechan
tumor
cell
kill
involv
deplet
amino
acid
block
protein
processingrecycl
well
toler
safe
administ
dose
result
metabolit
activ
evidenc
preclin
model
recent
tosedostat
demonstr
promis
efficaci
patient
acut
myeloid
leukemia
myelodysplast
syndrom
phase
ii
clinic
trial
activ
latter
subsequ
substitut
sulfur
contain
nucleophil
altern
mitsunobu
reaction
util
oh
replac
procedur
optic
activ
substrat
easili
avail
risk
racem
final
product
obtain
enantiomer
pure
form
mode
bind
metalloaminopeptidas
consid
typic
analogu
ntermin
portion
peptid
substrat
act
revers
competit
manner
thiol
group
termini
design
interact
noncoval
catalyt
metal
ion
except
function
group
essenti
polar
contact
contain
side
chain
occupi
pocket
despit
structur
simplic
low
molecular
weight
potenc
compound
metalloaminopeptidas
high
reason
strong
affin
sulfur
atom
dival
soft
acid
metal
ion
zn
ii
consequ
exhibit
much
higher
activ
amino
acid
analogu
correspond
complex
contain
metal
chelat
moieti
phosphon
hydroxam
one
frequent
compound
discrimin
affin
ratio
lower
comparison
analog
thiol
gener
onehand
inhibitor
direct
specif
toward
subsit
part
avail
extend
ligand
possess
addit
pn
portion
limit
complex
synthesi
diastereomer
puriti
nevertheless
found
fundament
practic
applic
connect
metalloaminopeptidas
inhibit
spectacular
achiev
associ
regul
action
aminopeptidas
n
enzym
involv
brain
renineangiotensin
cascad
repres
perspect
target
hypertens
therapi
seri
repres
deriv
natur
amino
acid
given
fig
llysin
thiol
absolut
configur
compound
shown
extrem
potent
inhibitor
arginyl
aminopeptidas
aminopeptidas
b
apb
subnanomolar
k
valu
lleucin
thiol
compound
bind
target
lower
activ
interestingli
exhibit
ratio
stereochem
prefer
toward
enzym
natur
configur
k
mm
r
enantiom
unexpectedli
compound
poorli
inhibit
leucin
aminopeptidas
lap
explain
use
zincmagnesium
hybrid
enzym
experi
accord
earlier
studi
lleucin
thiol
shown
potent
competit
inhibitor
microsom
aminopeptidas
porcin
kidney
apn
k
nm
compound
use
lead
structur
optim
size
neutral
hydrophob
residu
context
construct
potenti
analges
dual
inhibitor
neprilysin
nep
apn
broad
seri
inhibitor
synthes
show
high
equipot
efficaci
aminopeptidas
n
k
nm
among
methionin
thiol
compound
fig
appear
activ
vitro
least
four
order
magnitud
effect
carboxyl
phosphon
hydroxam
correspond
structur
despit
potenc
use
select
compound
intraven
administr
induc
antinocicept
respons
mice
hot
plate
test
evid
difficulti
cross
bloodebrain
barrier
inde
oxid
disulfid
form
increas
lipophil
made
effici
prodrug
much
signific
respons
stimul
applic
mix
prodrug
structur
disulfid
base
combin
two
thiol
inhibitor
direct
toward
certain
enzym
either
apn
nep
elucid
intrins
function
brain
therefor
medic
potenti
select
aminopeptidas
renineangiotensin
system
stimul
continu
studi
two
metalloaminopeptidas
name
apn
glutamyl
aminopeptidas
aminopeptidas
apa
suppos
particip
metabol
brain
angiotensin
ii
iii
angii
angiii
gluthiol
compound
fig
describ
first
effici
inhibitor
apa
howev
equipot
apn
k
versu
nm
respect
studi
physiolog
import
enzym
specif
agent
discrimin
two
target
high
degre
indispens
quest
select
inhibit
number
deriv
synthes
evalu
appear
rel
simpl
task
identifi
residu
respons
high
nanomolar
potenc
apn
ligand
extend
hydrophob
portion
favor
termin
heteroatom
group
exemplifi
compound
fig
repres
option
affin
compound
toward
apa
ratio
lower
anyway
accord
recent
data
lmethionin
thiol
develop
earlier
gave
even
apa
respect
conveni
modif
found
opposit
case
compromis
achiev
short
side
chain
acid
function
carboxyl
terminu
fig
affin
sulfon
acid
apa
elev
comparison
lead
drop
potenc
measur
apn
signific
final
result
discrimin
ratio
paramet
furthermor
improv
explor
sn
subsit
aminopeptidas
synthesi
tripeptidomimet
contain
optimum
substitu
attach
ntermini
dipeptid
librari
allow
determin
advantag
side
chain
bind
pocket
accommod
hydrophob
residu
wherea
pocket
prefer
neg
charg
residu
result
except
potent
compound
fig
character
strike
select
ratio
identifi
interestingli
activ
diastereoisom
exhibit
nonnatur
configur
r
portion
explain
steric
constrain
whole
molecul
despit
remark
activ
first
subnanomolar
thiol
inhibitor
apa
compound
poorli
bioavail
limit
fragment
optim
start
lead
gave
much
simpler
molecul
acid
substitut
atom
hydrophob
arylalkyl
fragment
result
satisfactori
potent
apa
inhibit
k
nm
howev
kinet
data
apn
report
overact
renineangiotensin
system
brain
implic
develop
mainten
hypertens
use
specif
agent
describ
demonstr
apa
apn
involv
metabol
angiotensin
ii
iii
respect
within
system
angiii
gener
angii
apa
assist
cleavag
ntermin
asparg
bond
wherea
apn
function
subsequ
inactiv
angiii
apa
specif
sulfon
increas
halflif
angii
mice
block
angii
angiii
convers
turn
control
vasopressin
releas
dosedepend
decreas
blood
pressur
achiev
intracerebroventricular
inject
contrarili
select
inhibitor
apn
administ
rout
caus
elev
blood
pressur
thu
level
angiotensin
ii
iii
brain
particular
control
aminopeptidas
suggest
potenti
target
hypertens
treatment
end
disulfid
dimer
lead
report
first
oral
avail
candid
therapi
base
aminopeptidas
inhibit
major
inhibitor
discov
metalloaminopeptidas
compound
interact
enzym
noncoval
way
howev
enzym
coval
inhibitor
also
found
fumagillin
acid
fig
ovalicin
fungal
metabolit
inhibit
methionin
aminopeptidas
type
format
coval
irrevers
bond
reactiv
epoxid
present
activ
center
enzym
compound
effect
toward
aminopeptidas
select
toward
complet
lack
select
toward
explain
differ
one
amino
acid
threonin
around
activ
center
enzym
determin
comparison
crystal
structur
approach
reveal
also
tight
bind
fumagillin
deriv
also
combin
sever
interact
made
inhibitor
compon
surfac
around
activ
center
enzym
biolog
studi
fumagillin
ovalicin
found
potent
inhibitor
angiogenesi
due
inhibit
endotheli
cell
prolifer
result
extens
sar
studi
synthesi
sever
deriv
compound
compound
fig
enter
clinic
trial
evalu
applic
antiangiogen
therapi
numer
competit
inhibitor
metalloaminopeptidas
recent
develop
frequent
start
lead
identifi
random
screen
eg
high
throughput
screen
util
fluorogen
chromogen
assay
virtual
screen
base
heteroatomrich
fragment
appropri
heteroaromat
rare
heterocycl
scaffold
contain
set
nitrogen
oxygen
andor
sulfur
atom
involv
coordin
catalyt
metal
ion
structur
rigid
constraint
portion
ligand
often
privileg
format
hydrophob
interact
specif
pep
stack
neighbor
residu
activ
site
synthet
procedur
use
obtain
compound
allow
combin
reliabl
method
substitu
diversif
perform
prior
ring
format
aromat
parallel
decor
target
scaffold
use
simpl
chemistri
amid
bond
format
extens
structur
optim
certain
scaffold
led
potent
inhibit
select
aminopeptidas
surprisingli
low
molecular
weight
compound
even
methionin
aminopeptidas
particularli
human
repres
exampl
success
applic
strategi
origin
describ
patent
literatur
potent
revers
nonpeptid
inhibitor
methionin
aminopeptidas
type
various
substitut
compound
bound
cobalt
form
affin
express
fig
biolog
relev
also
subsequ
present
iter
refin
inhibitor
lead
structur
allow
identif
compound
potenc
picomolar
rang
systemat
modif
key
structur
fragment
reveal
certain
tendenc
respons
elev
decreas
activ
substitut
anilin
phenyl
ring
small
residu
favor
compound
fig
contrarili
chang
optim
benzylthio
residu
structur
found
deleteri
similarli
methyl
triazol
nitrogen
atom
rel
smaller
extent
select
deriv
inhibit
human
endotheli
cell
prolifer
growth
new
blood
vessel
model
angiogenesi
low
molecular
weight
substitut
found
act
almost
equipot
revers
inhibitor
human
describ
deriv
diversif
posit
perform
use
variou
aromat
aldehyd
transform
appropri
alkyn
substrat
cycloaddit
sever
effect
ligand
cobaltactiv
identifi
show
k
app
valu
nm
exampl
k
app
nm
given
fig
correspond
k
nm
ic
nm
full
kinet
analysi
sar
studi
perform
phenyl
ring
exclud
bulki
substitut
show
small
alkyl
chain
toler
wherea
halogen
favor
posit
see
exampl
compound
fig
contrarili
addit
bulki
residu
even
heteroaromat
one
well
accept
indic
addit
room
activ
site
replac
whole
phenyl
ring
substitut
pyridyl
also
profit
use
pyrazol
base
scaffold
instead
triazol
one
reveal
key
role
atom
high
affin
regard
biolog
activ
compound
inhibit
human
mous
endotheli
cell
growth
enzymeligand
crystal
structur
accompani
studi
triazol
reveal
among
other
signific
aromat
ring
certain
size
substitut
present
potent
inhibitor
occupi
hydrophob
pocket
form
form
appropri
pep
stack
size
pocket
narrow
postul
discrimin
factor
two
form
methionin
aminopeptidas
differ
bind
affin
usual
order
magnitud
favor
triazol
studi
exampl
k
app
nm
versu
nm
ic
nm
versu
nm
fig
structur
data
provid
rational
sar
discuss
first
confirm
signific
key
interact
nitrogen
atom
inhibitor
cobalt
ion
molecular
mechan
triazol
action
elucid
origin
use
crystal
structur
staphylococcu
aureu
orthologu
enzym
complex
compound
fig
accord
result
triazol
nitrogen
atom
interact
one
two
cobalt
ion
nen
bond
nearli
colinear
co
co
distanc
nitrogen
coordin
cobalt
similar
tight
close
indic
strong
interact
triazol
ring
form
stack
contact
hydrophob
face
imidazol
side
chain
residu
believ
involv
catalyt
process
somewhat
surprisingli
substitu
substratelik
methionin
structur
dock
subsit
site
turn
natur
posit
occupi
thiobenzyl
residu
describ
metap
believ
dinuclear
cobalt
depend
enzym
co
ii
activ
known
form
howev
ident
metal
cofactor
still
ambigu
triazol
inhibit
exclus
cobaltactiv
human
even
high
nanomolar
potenc
although
fail
cell
prolifer
assay
use
shed
light
matter
metal
depend
action
indic
dival
ion
must
consid
relev
cofactor
particularli
respect
fact
architectur
enzym
activ
site
depend
ident
bound
metal
context
manganes
postul
physiolog
relev
metal
inde
triazol
investig
effect
toward
activ
metap
form
contrari
triazol
appear
select
inhibitor
methionin
aminopeptidas
type
bacteri
human
origin
essenti
function
bacteria
suggest
enzym
could
promis
target
develop
novel
broad
spectrum
antibiot
agent
accordingli
thiazol
base
activ
compound
identifi
screen
librari
toward
e
coli
methionin
aminopeptidas
worth
note
select
lead
repres
typic
heteroaromat
scaffold
central
core
molecul
rather
proxim
group
link
anoth
hydrophob
portion
frequent
heteroaromat
well
carbonecarbon
amid
carbonyl
base
bond
thu
complex
mode
enzym
catalyt
ion
characterist
triazol
usual
involv
particip
two
neighbor
heteroatom
group
random
screen
compound
nan
cowork
led
amid
acid
fig
inhibit
e
coli
ic
mm
serv
perspect
lead
compound
primari
chemic
mutat
basic
structur
chang
posit
pyridin
substitut
heteroatom
replac
isoster
group
appear
deleteri
potenc
probabl
combin
three
electroneg
group
involv
metal
ion
coordin
name
aromat
nitrogen
pyridin
ring
carbonyl
moieti
posit
heteroatom
thiazol
form
system
essenti
tight
bind
nevertheless
substitut
posit
pyridin
amid
ester
group
appear
profit
term
optim
interact
bind
pocket
affin
elev
nanomolar
rang
exampl
compound
fig
importantli
introduct
bulki
cyclic
aromat
residu
proxim
amid
allow
effici
discrimin
bacteri
enzym
differ
sourc
x
benzoyloamino
cyclohexanecarbamino
substitut
structur
select
factor
e
coli
saccharomyc
cerevisia
exceed
ratio
ic
mm
respect
ic
mm
compound
wide
optim
x
moieti
demonstr
introduct
addit
heteroatom
extend
amid
structur
also
well
toler
fig
final
replac
whole
pyridin
ring
anoth
thiazol
system
gave
compound
fig
low
nanomolar
potenc
interestingli
acid
select
inhibit
human
versu
exemplifi
differenti
factor
compound
fig
despit
moder
potenc
vitro
treatment
tumor
cell
line
specif
agent
suggest
role
g
phase
transit
furthermor
studi
confirm
previous
report
result
variat
metal
bind
activ
site
co
ii
ecmetap
presenc
thiazol
base
ligand
accord
appropri
crystal
structur
compound
seem
respons
drive
third
metal
ion
enzym
activ
site
auxiliari
cobalt
atom
present
nativ
enzym
even
crystal
presenc
high
concentr
metal
salt
addit
cobalt
interact
singl
histidin
residu
enzym
three
water
molecul
entranc
activ
center
two
nitrogen
atom
ligand
pyridin
amid
inhibitor
bind
stabil
sever
contact
mostli
hydrophob
charact
obvious
unusu
situat
must
taken
consider
sar
novel
metap
effector
discuss
vitro
versu
vivo
experi
data
correl
see
anoth
exampl
close
relat
thiazol
inhibitor
bacteri
methionin
aminopeptidas
discov
high
throughput
screen
ten
time
larger
librari
main
goal
studi
identif
potent
predominantli
select
inhibitor
could
distinguish
variou
metalloform
e
coli
metap
inde
thiazol
base
compound
exemplifi
compound
fig
strongli
inhibit
cobalt
depend
enzym
moder
manganes
iron
nickel
one
opposit
pattern
activ
found
heteroaromat
compound
acid
deriv
exhibit
prefer
toward
mn
ii
ecmetap
wherea
cathecholcontain
thiazol
prefer
fe
ii
ecmetap
howev
two
group
compound
follow
mode
bind
typic
heteroaromat
inhibitor
cobalt
form
metap
employ
heteroatom
ring
instead
bind
involv
two
proxim
oxygen
atom
either
carboxyl
phenol
moieti
respect
complex
metal
ion
direct
combin
two
heteroaromat
ring
repres
anoth
approach
develop
methionin
aminopeptidas
inhibitor
compound
bind
driven
activ
site
auxiliari
cobalt
ion
employ
nitrogen
atom
ring
place
coplanar
manner
thiabendazol
benzimidazol
substitut
posit
thiazol
ring
deriv
compound
fig
regul
co
ii
ecmetap
activ
k
valu
submicromolar
rang
although
appear
ineffect
vivo
explain
use
metapligand
crystal
structur
reveal
variat
metal
bind
activ
site
describ
acid
famili
relat
pyrimidin
identifi
upon
screen
member
librari
inhibitor
human
p
falciparum
methionin
aminopeptidas
interestingli
compound
virtual
equipot
toward
mammalian
type
enzym
exampl
see
fig
similarli
complex
auxiliari
co
ii
normal
involv
catalyt
process
nevertheless
appear
novel
potenti
antimalari
agent
three
activ
isoform
obtain
clone
express
purif
test
vitro
inhibitor
remark
select
toward
type
highest
obtain
potenc
ic
nm
activ
compound
inhibit
also
p
falciparum
prolifer
chloroquin
sensit
depend
erythrocyt
cultur
ic
mm
respect
consequ
compound
use
murin
malaria
model
posit
confirm
promis
target
develop
new
antimalari
boron
acid
inhibitor
aminopeptidas
describ
first
baker
et
al
aeromona
aminopeptidas
ec
report
simpl
aliphat
deriv
use
competit
transit
state
analogu
bound
activ
center
enzym
good
effici
among
five
test
deriv
acid
fig
best
inhibitor
enzym
anoth
approach
shenvi
describ
seri
aaminoboron
acid
effect
inhibitor
human
enkephalin
degrad
aminopeptidas
heda
microsom
leucin
aminopeptidas
cytosol
leucin
aminopeptidas
advantag
inhibitor
simpl
aliphat
deriv
presenc
free
amin
group
carbon
featur
known
improv
bind
ligand
aminopeptidas
detail
analysi
kinet
data
cytosol
leucin
aminopeptidas
reveal
biphas
slowbind
inhibit
mechan
aaminoboron
acid
suggest
slowbind
step
respons
format
tetrahedr
boron
molecul
trigon
boron
acid
inhibitori
activ
test
deriv
also
strongli
correl
side
chain
type
use
studi
fig
aldehyd
deriv
amino
acid
also
describ
inhibitor
aminopeptidas
andersson
et
al
first
report
group
compound
effect
transit
state
analogu
inhibitor
upon
hydrat
form
gemdiol
involv
zinc
complex
porcin
cytosol
microsom
leucin
aminopeptidas
effect
inhibitor
describ
report
lleucin
compound
fig
k
nm
lap
k
nm
apn
import
aldehyd
warhead
demonstr
report
comparison
valu
lleucin
inhibitori
constant
found
simpl
amino
acid
lleucin
well
hydroxi
deriv
lleucinol
compound
around
order
magnitud
less
effect
toward
aminopeptidas
test
addit
glycin
aldehyd
deriv
glycin
compound
fig
investig
studi
also
much
less
effect
k
mm
lap
result
confirm
import
side
chain
bind
effici
design
inhibitor
also
prove
inform
substrat
activ
screen
use
design
inhibitor
lleucin
pnitroanilid
substrat
much
effici
process
lap
analog
glycin
deriv
anoth
group
inhibitor
aminopeptidas
aldehyd
scaffold
propos
tarnu
et
al
deriv
respect
fig
compound
design
gener
inhibitor
metalloaminopeptidas
micromolar
competit
inhibitor
lap
apn
deriv
select
inhibit
apn
lap
observ
unfortun
due
suscept
oligomer
well
high
reactiv
aldehyd
deriv
best
candid
vivo
studi
howev
interest
altern
design
inhibitor
use
investig
aminopeptidas
vitro
sulfonamid
belong
group
recogn
compound
biomed
relev
easili
obtain
reaction
appropri
sulfonyl
chlorid
amin
offer
great
potenti
structur
variat
substrat
inde
sinc
discoveri
antimicrobi
properti
sulfonamid
found
vast
number
biolog
applic
connect
regul
enzymat
activ
context
proteas
inhibit
rational
sulfonamid
moieti
applic
isoster
isoelectron
resembl
high
energi
tetrahedr
transit
state
present
amid
bond
hydrolysi
similarli
phosphoru
contain
peptid
analogu
surprisingli
mani
recent
exampl
use
strategi
toward
metalloaminopeptidas
target
signific
mode
sulfonamid
action
rare
case
miscellan
follow
theoret
consid
pattern
transit
state
interact
titl
function
group
play
role
linker
hydrophob
portion
inhibitor
anoth
metal
bind
entiti
incorpor
one
altern
cooper
action
two
heteroatomrich
moieti
includ
sulfonamid
one
observ
advanc
studi
topic
seem
perform
abbott
laboratori
concern
anthranil
acid
sulfonamid
inhibitor
human
recombin
methionin
aminopeptidas
type
target
oral
avail
drug
anticanc
therapi
seri
sulfonamid
compound
fig
identifi
use
affin
select
mass
spectroscopi
screen
method
exhibit
micromolar
activ
manganes
form
human
moder
potent
cell
prolifer
assay
thank
promis
pharmacokinet
synthet
viabil
point
novel
attract
lead
consecut
xray
studi
allow
ration
design
new
gener
ligand
track
effici
structur
optim
first
iter
ic
enlarg
aromat
portion
anthranil
acid
naphthalen
tetrahydronaphthalen
system
compound
fig
allow
improv
activ
start
molecul
reveal
crystal
structur
tetrahydronaphthyl
ring
fit
tightli
hydrophob
pocket
activ
site
carboxyl
actual
metal
chelat
group
wherea
sulfonamid
moieti
simpli
ensur
proper
twist
molecul
point
aromat
ring
lipophil
environ
unfortun
inhibitor
exhibit
limit
cellular
activ
extens
bind
human
serum
albumin
posit
charg
ortho
substitut
arylsulfonamid
ring
predict
obey
drawback
particular
disrupt
interact
albumin
set
substitu
structur
base
complex
amin
diamin
introduc
posit
posit
valid
approach
modifi
product
exemplifi
fig
show
potent
activ
associ
high
select
versu
relat
aminopeptidas
ratio
less
activ
exampl
importantli
effici
cell
prolifer
assay
improv
greater
gain
potenc
rank
low
nanomolar
rang
similar
paramet
achiev
disubstitut
anthranil
acid
contain
addit
heteroatom
group
presum
tighten
interact
manganes
ion
sinc
exhibit
strong
anticanc
activ
enhanc
access
oral
avail
sulfonamid
could
consid
optim
therapeut
use
cooper
bind
mode
observ
quinolinebas
sulfonamid
potent
toward
e
coli
inhibitor
discov
screen
member
small
organ
compound
librari
select
hit
screen
differ
metalloform
enzym
highest
affin
toward
cobalt
form
display
compound
fig
sulfonamid
behav
typic
competit
inhibitor
howev
disclos
xray
structur
studi
mode
interact
typic
consist
data
describ
heteroaromat
ligand
enzym
activ
site
load
three
metal
ion
inhibitor
bound
bident
sulfonamid
quinolin
n
n
donor
auxiliari
manganes
cobalt
atom
although
methanesufon
fragment
deepli
buri
molecul
direct
interact
catalyt
metal
ion
tetralon
deriv
first
describ
schalk
et
al
deriv
found
nanomolar
inhibitor
porcin
kidney
aminopeptidas
n
compound
fig
nonpeptid
charact
competit
inhibitor
enzym
possibl
mechan
coordin
enzym
zinc
ion
via
carbonyl
amin
group
locat
neighbor
carbon
cyclohexyl
scaffold
interestingli
compound
almost
complet
inact
toward
aspart
arginin
aminopeptidas
slightli
activ
toward
lap
anoth
approach
albrecht
et
al
synthes
variou
new
deriv
sever
methyl
keton
substitut
oxim
hydroxam
acid
phosphin
acid
hydrazid
deriv
exemplifi
compound
fig
obtain
test
toward
leucin
aminopeptidas
aminopeptidas
n
aeromona
proteolytica
aminopeptidas
leukotrien
hydrolas
even
theoret
equip
better
zinc
chelat
group
compound
rather
weak
low
micromolar
k
valu
inhibitor
aminopeptidas
one
activ
site
zinc
weak
inhibitor
aminopeptidas
two
zinc
ion
inhibitor
bear
gallic
acid
structur
design
base
previous
known
biolog
properti
compound
well
assumpt
methoxi
natur
gallic
acid
three
free
hydroxi
group
substitut
hydrophob
ring
compound
tightli
bind
pocket
aminopeptidas
n
sever
amino
acid
deriv
compound
like
lisoglutamin
cyclolisoglutamin
obtain
among
gallolylamid
deriv
base
prolin
scaffold
compound
fig
extrem
good
inhibitor
aminopeptidas
n
best
compound
ic
valu
low
nanomolar
rang
anoth
studi
lisoglutamin
cyclolisoglutamin
deriv
compound
fig
synthes
compound
good
inhibitor
prolin
deriv
ic
betulin
acid
fig
triterpen
isol
bark
sever
differ
plant
birch
bark
rich
sourc
compound
compound
found
potent
induc
apoptosi
cancer
cell
current
clinic
trial
propos
betulin
acid
act
increas
mitochondri
membran
permeabl
subsequ
facilit
releas
apoptosi
stimul
protein
cytochrom
c
howev
sever
other
biolog
target
compound
propos
one
membran
aminopeptidas
n
melzig
et
al
determin
ic
betulin
acid
aminopeptidas
mm
natur
occur
plant
polyphenolecurcumin
fig
also
describ
inhibitor
aminopeptidas
n
curcumin
known
potent
antitumor
agent
current
mechan
action
well
biolog
target
extens
investig
compound
interact
irrevers
noncompetit
mode
strongli
inhibit
apnposit
tumor
cell
invas
well
induc
angiogenesi
basic
fibroblast
growth
factor
interestingli
curcumin
influenc
invas
apnneg
cell
strengthen
hypothesi
antiinvas
activ
compound
result
inhibit
aminopeptidas
play
pivot
role
turnov
protein
regul
intracellular
amino
acid
pool
essenti
metabol
growth
develop
cell
tissu
part
process
regul
immun
neurolog
system
also
perform
broad
spectrum
function
outsid
cell
surfac
even
surround
milieu
receptor
hormon
process
regul
etc
involv
caus
mainten
certain
patholog
diseas
particularli
cancer
focus
attent
structur
function
hope
develop
new
treatment
recent
learn
aminopeptidas
also
central
cellular
physiolog
mani
parasit
includ
malaria
open
new
avenu
develop
antiinfecti
diseas
drug
crucial
develop
new
drug
howev
detail
understand
mechan
bind
interact
inhibitori
compound
activ
site
target
present
review
highlight
progress
well
sever
aminopeptidas
includ
leucin
alanin
methionin
aminopeptidas
also
expos
lack
inform
larg
number
aminopeptidas
famili
clearli
gap
fill
time
due
improv
inhibitor
discoveri
design
eg
screen
chemic
librari
follow
medicin
chemistri
method
threedimension
structur
determin
challeng
discov
inhibitor
select
specif
enzym
type
avoid
offtarget
effect
system
deliv
block
specif
function
physiolog
role
particular
aminopeptidas
sinc
enzym
often
perform
varieti
defin
ancillari
role
